Latest News and Press Releases

Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes MannKind’s Chief Medical Officer Presenting New Afrezza® Data Released at American Diabetes...

Study achieved primary endpoint of safety and tolerabilityProgressive dosing of Treprostinil Technosphere (TreT) significantly exceeded the corresponding peak plasma and exposure levels of the maximum...

WESTLAKE VILLAGE, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) has established a stock purchase plan that provides MannKind’s directors and executive officers with a...

Q1 2018 Afrezza Net Revenue was $3.4 million; +184% vs. Q1 2017 (+234% under the 2017 revenue recognition model)Q1 2018 Net Cash Used in Operating Activities was $21.7 millionSTAT study results...

WESTLAKE VILLAGE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients...

WESTLAKE VILLAGE, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 first quarter financial results on Wednesday, May 9, 2018 and its management...

WESTLAKE VILLAGE, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with...

WESTLAKE VILLAGE, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the completion of its previously announced registered direct offering of 14,000,000...

WESTLAKE VILLAGE, Calif., April 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the pricing of a registered direct offering of 14,000,000 shares of common stock and...

WESTLAKE VILLAGE, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with...